Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. Doykov et al
This data relates to the paper 'Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response by I Doykov et al. Determining the protection an individual has to SARS-CoV-2 variants of concern (VoC) is crucial for future immune surveillance, vaccine development and understanding the changing immune response. We devised a more informative assay to current ELISA based serology using multiplexed, baited, targeted-proteomics for direct detection of multiple proteins in the SARS-CoV-2 anti-spike antibody immunocomplex. Serum from individuals collected after infection, or first and second dose vaccination demonstrate this approach shows concordance with existing serology and neutralisation. Our assays show altered responses of both immunoglobulins and complement to the Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.1) VoC. and a reduced response to Omicron (B1.1.1529). We were able to identify individuals who had prior infection, and observed that C1q is closely associated with IgG1 (r>0.82) and may better reflect neutralisation to VoC. Analysing additional immunoproteins beyond IgG, provides important information about our understanding of the response to infection and vaccination. The skyine raw data files are provided and the processed data given in the data set which includes the ratio measurements of each protein measured in the immunocomplex assay used on samples from healthcare workers vaccinated and or infected to SARS-CoV2. Quality control assay data are also provided for each peptide/protein in a separate tab.
Steps to reproduce
Detailed STAR methods are available in the related publication Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. Doykov et al